iDEL Therapeutics GmbH

About iDEL Therapeutics GmbH

iDEL Therapeutics is a biotechnology company developing a pioneering drug delivery platform designed to transport therapeutic payloads directly into the cytosol of tumor cells. Our proprietary synthetic shuttle technology leverages a unique pan-cancer uptake mechanism that enables high intracellular drug exposure and sustained tumor retention while evading endosomal trapping. The platform is compatible with both small and large molecules, including nanobody-based therapeutics targeting oncogenes and tumor-directed cytotoxic payloads. iDEL Therapeutics is advancing a pipeline of innovative cancer therapies designed to unlock historically undruggable intracellular targets. Our mission is to transform the cancer treatment paradigm by expanding therapeutic windows, improving treatment flexibility, and delivering meaningful benefits for patients across multiple cancer indications. Learn more at: https://idel-tx.com